NLR (Neutrophil–Lymphocyte Ratio): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

The neutrophil–lymphocyte ratio (NLR) is a simple, inexpensive, and widely available inflammatory marker derived from the complete blood count with differential. It is calculated by dividing the absolute neutrophil count by the absolute lymphocyte count.

NLR reflects the dynamic balance between two key arms of the immune system:

· Neutrophils are the frontline responders of the innate immune system. They phagocytose pathogens, release cytotoxic granules, and form neutrophil extracellular traps. They are rapidly mobilised during acute inflammation, infection, and tissue injury. Persistent neutrophilia signals ongoing systemic inflammation.

· Lymphocytes are the orchestrators of adaptive immunity. They include T cells, B cells, and natural killer cells. They mediate pathogen‑specific responses, immunological memory, and immune regulation. Lymphopenia reflects physiological stress, immunosuppression, or exhaustion of the adaptive immune reservoir.

An elevated NLR indicates either neutrophilia (increased innate inflammatory activity), lymphopenia (suppressed adaptive immunity), or both. This pattern signals immune dysregulation, systemic inflammation, and physiological stress. A low NLR generally reflects balanced immunity and low inflammatory activity.

Clinical utility: NLR is not a diagnostic test but a prognostic and risk‑stratification marker. It has been extensively validated across multiple disciplines:

· Cardiovascular disease: NLR predicts major adverse cardiac events, mortality after myocardial infarction, stroke severity, and outcomes in heart failure.

· Oncology: Pre‑treatment NLR independently predicts poorer survival in solid tumours (colorectal, lung, breast, pancreatic, hepatocellular) and haematological malignancies.

· Infectious diseases: NLR correlates with severity in sepsis, COVID‑19, pneumonia, and tuberculosis; it aids early identification of patients requiring intensive care.

· Autoimmune / inflammatory disorders: NLR reflects disease activity in rheumatoid arthritis, lupus, inflammatory bowel disease, and vasculitis.

· Critical care: NLR at admission predicts mortality in intensive care unit patients.

· Surgical risk: Preoperative NLR predicts postoperative complications and long‑term outcomes.

NLR is cheap, universally available, can be trended serially, and is less susceptible to isolated fluctuations than absolute cell counts. It must always be interpreted alongside the clinical context, absolute neutrophil and lymphocyte counts, and other inflammatory markers (CRP, ESR).

---

2. What does it measure

a. Units of measurement

· Dimensionless ratio – calculated as:

· NLR = Absolute neutrophil count (×10⁹/L or /μL) ÷ Absolute lymphocyte count (×10⁹/L or /μL)

· Since both numerator and denominator share the same unit, the ratio is unit‑free.

b. Normal Range and Optimal Targets

(Reference intervals vary by age, ethnicity, and laboratory; the following are derived from large population studies and prognostic cut‑points.)

Adults:

· Optimal / low risk: NLR less than 2.0

· Normal / acceptable: NLR 2.0–3.0

· Borderline elevated: NLR 3.0–5.0

· Elevated / adverse prognosis: NLR 5.0–7.0

· Severely elevated / high risk: NLR greater than 7.0

Children:

· Normal ranges are age‑dependent; infants and young children have physiologically higher lymphocyte counts and lower neutrophil counts, resulting in lower NLR.

· Infants: 0.5–2.0

· Children >2 years: progressively approach adult ranges by adolescence.

· Use age‑matched reference ranges from the reporting laboratory.

Elderly:

· Mild age‑related increase in NLR (0.5–1.0 unit) due to immunosenescence – reduced lymphocyte production, preserved neutrophil function.

Interpretation notes:

· NLR is a continuous variable; there is no universal threshold. Different diseases and clinical contexts use different cut‑points.

· Isolated elevated NLR with normal absolute counts should prompt repeat testing; transient stress, dehydration, or occult infection may cause temporary elevation.

· Very low NLR (<1.0) is uncommon in adults and may indicate neutropenia or lymphocytosis; investigate if persistent.

· Always examine the absolute neutrophil and lymphocyte counts – the ratio alone does not reveal which lineage is deranged.

· NLR is dynamic – it rises within hours of acute stress (surgery, trauma, infection) and falls with recovery.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise NLR)

NLR is increased by neutrophilia, lymphopenia, or both.

Factors that cause neutrophilia (↑ neutrophils, ↑ NLR):

· Acute inflammation / infection: bacterial infections, sepsis, abscess, appendicitis, pneumonia, pyelonephritis.

· Tissue injury / necrosis: surgery, trauma, burns, myocardial infarction, pancreatitis, fracture.

· Chronic inflammation: rheumatoid arthritis, gout, vasculitis, inflammatory bowel disease.

· Malignancy: solid tumours (paraneoplastic neutrophilia), myeloproliferative neoplasms, chronic myeloid leukaemia.

· Medications: corticosteroids, lithium, beta‑agonists, granulocyte colony‑stimulating factor (G‑CSF).

· Metabolic: diabetic ketoacidosis, uraemia, eclampsia.

· Haematological: asplenia, haemolytic anaemia, haemorrhage.

· Physiological: pregnancy (third trimester), exercise, stress, smoking.

Factors that cause lymphopenia (↓ lymphocytes, ↑ NLR):

· Acute stress / critical illness: trauma, surgery, myocardial infarction, sepsis – cortisol‑mediated.

· Infections: viral (HIV, influenza, COVID‑19, hepatitis), bacterial sepsis, tuberculosis.

· Immunosuppressive therapy: corticosteroids, chemotherapy, radiation, calcineurin inhibitors, mycophenolate.

· Autoimmune diseases: SLE, rheumatoid arthritis, sarcoidosis.

· Malnutrition / protein‑energy wasting: alcoholism, anorexia nervosa.

· Genetic: DiGeorge syndrome, severe combined immunodeficiency (SCID).

· Haematological: aplastic anaemia, advanced lymphoma, leukaemia.

· Ageing: physiological decline in T‑cell production.

Thus, elevated NLR is associated with:

· Acute and chronic inflammation.

· Infection (bacterial > viral).

· Tissue ischaemia and necrosis.

· Malignancy.

· Immunosuppression (therapeutic or disease‑induced).

· Physiological stress.

· Poor nutritional status.

· Advanced age and frailty.

b. Indirect correlation (factors that influence NLR interpretation or cause artefactual changes)

· Circadian rhythm: neutrophil and lymphocyte counts exhibit diurnal variation; lymphocytes peak at night, neutrophils relatively stable. NLR is lowest in the morning. For serial comparisons, collect blood at a consistent time.

· Exercise: intense acute exercise causes transient neutrophilia and lymphocytosis, followed by delayed lymphopenia. Defer testing after strenuous exertion.

· Pregnancy: neutrophils rise progressively; lymphocytes decline slightly. NLR increases physiologically in the third trimester. Not a reliable marker during pregnancy.

· Smoking: chronic smokers have elevated leukocytes, particularly neutrophils; NLR is chronically elevated.

· Alcohol: chronic alcoholism causes lymphopenia and may elevate NLR; acute alcohol intake can suppress neutrophil function.

· Medications:

· Increase NLR: corticosteroids, G‑CSF, epinephrine, lithium.

· Decrease NLR: immunosuppressants (azathioprine, mycophenolate), chemotherapy (may cause neutropenia).

· Ethnicity: African and Afro‑Caribbean populations have physiologically lower neutrophil counts (benign ethnic neutropenia). NLR may be lower for the same inflammatory stimulus; reference ranges should ideally be stratified.

· Splenectomy: neutrophilia without lymphopenia → NLR increases.

· Assay variability: automated haematology analysers may misclassify blasts, immature granulocytes, or atypical lymphocytes; manual differential is gold standard for abnormal flags.

---

4. Disorders related to abnormal values

a. When NLR is elevated (clinically significant – adverse prognostic marker)

Cardiovascular disease:

· Acute coronary syndrome / myocardial infarction: Elevated NLR at presentation independently predicts in‑hospital mortality, heart failure, recurrent ischaemia, and long‑term death. NLR >5.0 is a high‑risk feature.

· Ischaemic stroke: NLR correlates with infarct volume, haemorrhagic transformation, and 30‑day mortality.

· Heart failure: NLR predicts hospitalisation and cardiovascular death.

· Peripheral arterial disease: NLR associates with disease severity and amputation risk.

Oncology:

· Solid tumours: Pre‑treatment NLR >3.0–5.0 (varies by tumour type) predicts poorer overall and progression‑free survival in colorectal, lung, breast, gastric, pancreatic, hepatocellular, and renal cell carcinoma.

· Haematological malignancies: Elevated NLR at diagnosis correlates with aggressive disease in lymphoma, leukaemia, and multiple myeloma.

· Surgical oncology: Preoperative NLR predicts postoperative complications and recurrence.

Infectious diseases:

· Sepsis / bacteraemia: NLR >10–12 strongly suggests bacterial infection and predicts progression to septic shock and death. NLR trends guide antibiotic response.

· COVID‑19: NLR >3.5–5.0 at admission identifies patients at high risk of severe disease, intensive care admission, and mortality.

· Pneumonia: NLR >10 correlates with complicated parapneumonic effusion and empyema.

· Tuberculosis: NLR correlates with disease extent and cavitation.

Autoimmune / inflammatory diseases:

· Rheumatoid arthritis, SLE, inflammatory bowel disease: NLR reflects disease activity; normalises with successful immunosuppression.

· Vasculitis: Elevated NLR at diagnosis predicts relapses.

· Sarcoidosis: NLR associates with progressive pulmonary disease.

Critical care / surgery:

· ICU admission: NLR >7–10 independently predicts mortality.

· Postoperative: Persistent NLR elevation >5 on day 3–5 predicts infective complications and anastomotic leak.

Other:

· Chronic kidney disease: NLR predicts cardiovascular events and progression to end‑stage renal disease.

· Diabetes: NLR correlates with glycaemic control and diabetic complications.

· Frailty / malnutrition: NLR is a marker of immunosenescence and poor prognosis in the elderly.

b. When NLR is low (usually favourable, but context‑dependent)

· Generally desirable: low NLR indicates balanced immunity and low inflammatory activity.

· Physiological: children, healthy adults with regular exercise, non‑smokers.

· Lymphocytosis: infections (EBV, pertussis, CMV), chronic lymphocytic leukaemia – NLR may be very low, but this is not protective if due to malignancy.

· Neutropenia: chemotherapy, bone marrow failure, benign ethnic neutropenia – NLR may be low, but this confers infection risk.

· Recovery phase: after bone marrow transplant or chemotherapy, lymphocyte recovery may precede neutrophil recovery, transiently lowering NLR.

Interpretation note: An isolated low NLR in an otherwise healthy, asymptomatic individual with normal absolute counts is not a cause for concern and does not require investigation.

---

5. Best way to address aberrant levels

Important principle: NLR is a marker, not a disease. There is no treatment to directly normalise NLR. Intervention must target the underlying condition causing neutrophilia or lymphopenia. Normalising NLR is a sign that the underlying disease is controlled, inflammation is subsiding, physiological stress is resolving, or nutritional status is improving.

a. Quick ways or using Medications

There is no medication approved specifically to lower NLR. The following interventions address the underlying causes:

For neutrophilia:

· Treat infection: appropriate antimicrobial, antiviral, or antifungal therapy.

· Control inflammation: disease‑modifying antirheumatic drugs (DMARDs), biologics, corticosteroids for autoimmune flares.

· Treat malignancy: surgery, chemotherapy, radiotherapy, targeted therapy.

· Remove causative medication: if drug‑induced (corticosteroids, lithium, G‑CSF), taper or switch if clinically feasible.

· Manage metabolic causes: insulin for diabetic ketoacidosis, dialysis for uraemia.

For lymphopenia:

· Treat underlying infection: antiretroviral therapy for HIV, antiviral agents.

· Reduce immunosuppression: taper corticosteroids when possible, switch to less lymphotoxic agents.

· Nutritional repletion: correct deficiencies of protein, zinc, vitamin B12, folate.

· Treat autoimmune disease: immunosuppressive therapy may cause lymphopenia; balance disease control against lymphocyte preservation.

For acute stress / critical illness:

· Haemodynamic stabilisation: fluids, vasopressors, source control.

· Supportive care: adequate oxygenation, nutrition, glycaemic control.

Do not self‑prescribe – all prescription medications require medical supervision.

b. Using Supplements or Holistic medicine

Supplements with evidence for supporting neutrophil–lymphocyte balance – as adjuncts to definitive therapy:

· Omega‑3 fatty acids (EPA/DHA):

· Reduce systemic inflammation, may lower neutrophil counts and neutrophil activation.

· Preferred source: Algae oil – sustainable, plant‑based, direct EPA/DHA, no marine contaminants.

· Avoid conventional fish oil (overfishing, ocean pollution, ethical concerns).

· Dose: 2–4 g/day EPA/DHA for anti‑inflammatory effect.

· Vitamin D:

· Deficiency is associated with immune dysregulation and elevated inflammatory markers.

· Supplementation reduces neutrophil‑mediated inflammation and supports lymphocyte function.

· Preferred: D3 (cholecalciferol) from lichen.

· Dose: 600–2000 IU/day for maintenance; higher doses for deficiency correction (under guidance).

· Zinc:

· Essential for lymphocyte development and function; deficiency causes lymphopenia.

· Supplementation in deficient individuals increases lymphocyte counts and may lower NLR.

· Preferred form: zinc picolinate or zinc citrate.

· Dose: 15–30 mg elemental zinc/day; monitor copper with long‑term use.

· Vitamin C:

· Antioxidant; may reduce neutrophil oxidative burst and attenuate inflammation.

· High‑dose intravenous vitamin C used experimentally in sepsis; oral supplementation for NLR improvement lacks robust evidence.

· Curcumin (turmeric):

· Anti‑inflammatory; inhibits neutrophil activation and reduces pro‑inflammatory cytokines.

· Use phytosomal, liposomal, or with piperine for bioavailability.

· Avoid products with added synthetic folic acid or cyanocobalamin.

· Green tea catechins (EGCG):

· Anti‑inflammatory, immunomodulatory; may suppress neutrophil recruitment.

· Use beverage (2–3 cups/day) rather than concentrated extracts (hepatotoxicity risk).

· Ashwagandha (Withania somnifera):

· Adaptogen; may reduce stress‑induced lymphopenia and cortisol‑mediated neutrophilia.

· Limited evidence; use standardised extracts from GMP‑certified manufacturers.

· Reishi mushroom (Ganoderma lucidum):

· Beta‑glucans; immunomodulatory, may enhance lymphocyte activity and modulate neutrophil function.

· Preferred source: fruiting body extract, certified organic.

· Probiotics / prebiotics:

· Modulate gut microbiota; emerging evidence suggests they may reduce systemic inflammation and improve immune balance.

· Preferred sources: fermented plant foods (kimchi, sauerkraut, kombucha); standardised probiotic supplements with documented strains.

· Vitamin B12 and folate:

· Deficiency causes ineffective haematopoiesis, including lymphopenia.

· Use methylcobalamin and methylfolate – active forms, avoid synthetic folic acid and cyanocobalamin.

· Dose: methylcobalamin 1000–2000 mcg/day, methylfolate 400–1000 mcg/day if deficient.

· Selenium:

· Co‑factor for antioxidant enzymes; deficiency impairs lymphocyte proliferation.

· Supplementation in deficient individuals may improve immune function.

Supplements to avoid:

· Products with added synthetic folic acid or cyanocobalamin – use methylfolate and methylcobalamin if needed.

· Unregulated herbal blends with undisclosed ingredients.

· High‑dose vitamin E – may impair immune function.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

Diet is a cornerstone of inflammation control and immune balance. A well‑designed, nutrient‑dense plant‑based diet supports lymphocyte function, modulates neutrophil activity, and promotes a favourable NLR.

Core dietary principles – what to emphasise:

· Anti‑inflammatory dietary pattern:

· Mediterranean‑style plant‑forward diet – abundant vegetables, fruits, legumes, whole grains, nuts, seeds, olive oil.

· High in polyphenols, fibre, unsaturated fats, and antioxidants.

· Low in refined carbohydrates, added sugars, and saturated fats.

· Consistently associated with lower inflammatory markers, including CRP and IL‑6.

· Adequate protein intake:

· Essential for lymphocyte synthesis and immune competence.

· Plant‑based protein sources (hierarchy adhered):

· Primary: legumes (lentils, chickpeas, beans, soy products – tofu, tempeh, edamame).

· Fungi / algae: mycoprotein (Quorn), spirulina, chlorella.

· Biotechnology: precision‑fermented dairy proteins (animal‑free whey, casein) – acceptable emerging options.

· Dairy / eggs: permitted but not emphasised; low‑fat fermented dairy (yoghurt, kefir) if tolerated.

· Meat, poultry, fish: deliberately omitted. Effective plant‑based alternatives exist to meet all protein requirements for immune health.

· Zinc‑rich plant foods:

· Pumpkin seeds, hemp seeds, chickpeas, lentils, cashews, quinoa.

· Soaking and sprouting legumes and seeds reduces phytate and enhances zinc absorption.

· Vitamin B12:

· No reliable plant‑based whole food source. Must be supplemented or obtained from fortified foods (plant milks, nutritional yeast with methylcobalamin).

· Precision‑fermented B12 – ecologically responsible, non‑animal, preferred.

· Folate:

· Abundant in leafy greens, legumes, asparagus, beets, sunflower seeds.

· Deficiency impairs lymphocyte proliferation.

· Vitamin C‑rich foods:

· Citrus fruits, guava, bell peppers, broccoli, kiwi, strawberries, amla (Indian gooseberry).

· Vitamin D:

· Sunlight exposure primary; fortified plant milks; supplement from lichen if needed.

· Iron:

· Iron deficiency impairs lymphocyte function and may cause reactive thrombocytosis.

· Plant sources: lentils, chickpeas, tofu, pumpkin seeds, quinoa, fortified cereals.

· Enhance absorption with vitamin C; avoid tea/coffee with meals.

· Selenium:

· Brazil nuts (1–2 per day), sunflower seeds, mushrooms, whole grains.

· Omega‑3 fatty acids:

· ALA sources: ground flaxseeds, chia seeds, hemp seeds, walnuts.

· Direct EPA/DHA: microalgae (spirulina, chlorella – limited amounts); algae oil supplements for therapeutic doses.

· Polyphenol‑rich foods:

· Berries, green tea, dark chocolate (≥70% cocoa), extra virgin olive oil, turmeric, ginger, cruciferous vegetables.

· Fermented plant foods:

· Kimchi, sauerkraut, kombucha, miso, tempeh – support gut microbiome diversity and reduce systemic inflammation.

· Mushrooms:

· Shiitake, maitake, oyster, reishi – beta‑glucans and ergothioneine; immunomodulatory.

What to avoid or severely limit:

· Ultra‑processed foods, refined carbohydrates, added sugars – promote inflammation and impair immune function.

· Excess alcohol – causes lymphopenia and may elevate NLR; abstinence recommended if NLR is persistently elevated.

· Trans fats – partially hydrogenated oils.

· Saturated fats – excess intake may promote inflammation.

· Red and processed meats – associated with systemic inflammation; not required.

· Smoking – single most important modifiable risk factor for elevated NLR; cessation reduces neutrophil counts and improves lymphocyte function.

Lifestyle factors with proven benefit for NLR:

· Regular moderate aerobic exercise: 30–60 minutes, most days – reduces resting neutrophil counts, enhances lymphocyte circulation, and lowers NLR.

· Stress reduction: chronic stress elevates cortisol, causing neutrophilia and lymphopenia; mindfulness, meditation, yoga, adequate sleep.

· Smoking cessation: NLR decreases within weeks to months of quitting.

· Weight loss: in overweight/obese individuals, 5–10% weight loss reduces systemic inflammation and improves NLR.

· Sleep hygiene: 7–9 hours of quality sleep per night supports adaptive immunity.

---

6. How soon can one expect improvement and the ideal time frame to retest

NLR is highly dynamic and responds rapidly to acute changes – within hours to days.

For acute conditions (infection, surgery, trauma, myocardial infarction):

· NLR peaks 24–72 hours after insult.

· With effective treatment and clinical recovery, NLR begins to decline within 3–7 days.

· Normalisation typically occurs within 1–2 weeks in uncomplicated cases.

· Repeat testing: at 48–72 hours to assess response to therapy; at 1–2 weeks to confirm resolution.

For chronic inflammatory / autoimmune diseases:

· After initiating or adjusting immunosuppressive therapy (corticosteroids, DMARDs, biologics), NLR improvement is detectable in 2–4 weeks.

· Maximal response at 8–12 weeks.

· Repeat testing: every 4–8 weeks during dose titration; every 3–6 months in stable disease.

For nutritional deficiencies (zinc, B12, folate, vitamin D):

· Supplementation in deficient individuals improves lymphocyte counts within 2–4 weeks.

· NLR improvement over 4–8 weeks.

· Repeat testing: at 2–3 months.

For lifestyle interventions:

· Smoking cessation: NLR begins to decrease within 2–4 weeks; maximal effect at 3–6 months.

· Weight loss / exercise: NLR improvement detectable in 3–6 months with sustained lifestyle change.

· Alcohol abstinence: NLR declines within 2–4 weeks.

For malignancy on treatment:

· NLR trends are used prognostically; improvement after surgery, chemotherapy, or targeted therapy may take 1–3 months.

· Persistent elevation despite treatment suggests residual disease or poor response.

Retesting interval summary:

· Acute illness / hospitalisation: repeat every 48–72 hours until trending downward; then 1–2 weeks after discharge.

· Chronic disease on treatment: every 3–6 months.

· Nutritional intervention: repeat at 2–3 months.

· Lifestyle modification: repeat at 3–6 months.

· Routine health screen: every 1–2 years in stable, healthy individuals.

Do not retest NLR more often than every 48 hours in acute settings (faster than this, changes reflect diurnal variation rather than true trend); in stable chronic disease, no more often than every 4 weeks.

---

Conclusion

The neutrophil–lymphocyte ratio is a distillation of two fundamental forces in human immunity: the rapid, destructive power of innate inflammation and the precise, memory‑driven defence of adaptive immunity. An elevated NLR signals that the balance has shifted – the inflammatory foot is on the accelerator, the adaptive brake is failing, or both.

This ratio is not a diagnosis; it is a warning. It tells the clinician that the body is under physiological stress, that systemic inflammation is present, and that the adaptive immune system is struggling to keep pace. In acute myocardial infarction, it predicts which patients will develop heart failure. In sepsis, it identifies those who will deteriorate. In cancer, it whispers which tumours will resist therapy and which patients will survive.

There is no direct treatment for an elevated NLR. The ratio falls only when the underlying condition is addressed – the infected source drained, the ischaemic vessel revascularised, the autoimmune flare quelled, the nutritional deficiency corrected, the cigarette extinguished.

A plant‑based, ecologically responsible diet – rich in legumes, whole grains, nuts, seeds, mushrooms, and algae‑derived omega‑3s – provides the nutritional foundation for immune resilience. It supplies the zinc, protein, folate, and antioxidants required for lymphocyte health, while its anti‑inflammatory polyphenols and fibre calm the neutrophil response. Meat is not required; its displacement by plants is itself an anti‑inflammatory intervention.

NLR is a number. It is also a narrative of inflammation and immunity, stress and recovery, disease and healing. Learn to read it – and then learn to act.

---x-x-

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x-